India's Central Drugs Standard Control Organisation (CDSCO) has granted approval for Astellas Pharma's Padcev (enfortumab vedotin) as a first-line treatment for advanced bladder cancer. This marks a significant milestone in oncology, providing a new therapeutic option for patients with locally advanced or metastatic urothelial carcinoma.
Breakthrough Therapy for Bladder Cancer
Padcev is an antibody-drug conjugate that targets Nectin-4, a protein highly expressed in bladder cancer cells. It combines a monoclonal antibody with a chemotherapy agent, delivering cytotoxic drugs directly to cancer cells while minimizing damage to healthy tissues. The approval is based on results from the Phase 3 EV-302 clinical trial, which demonstrated significant improvements in overall survival and progression-free survival compared to standard chemotherapy.
Clinical Trial Outcomes
The EV-302 trial enrolled over 800 patients across multiple countries. Results showed that Padcev in combination with pembrolizumab reduced the risk of death by 53% and delayed disease progression by 55% compared to platinum-based chemotherapy. These findings led to the drug's approval in several countries, including the United States and European Union, before India.
Impact on Indian Patients
Bladder cancer is the tenth most common cancer globally, with India reporting an increasing incidence. The approval of Padcev offers a new frontline option for patients who previously had limited choices after platinum-based chemotherapy. The drug is administered intravenously, and common side effects include rash, fatigue, and peripheral neuropathy. Astellas Pharma has not yet disclosed the pricing for the Indian market, but patient access programs may be considered.
Regulatory Process and Future Prospects
The CDSCO approval followed a rigorous review of safety and efficacy data. The drug was previously approved in India for later-line treatment in 2021. With this expanded indication, Padcev is expected to become a standard of care for advanced bladder cancer. Astellas is also exploring other combinations and indications for the drug, including earlier stages of the disease.
